Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

Translated title of the contribution: Efficacy and safety of Levetiracetam as add-on therapy in patients with refractory partial epilepsy: A long-term, open-label, prospective study

A. La Neve, G. Boero, M. Stuppiello, A. Papantonio, N. Specchio, P. D'Alessandro, A. De Palo, G. De Agazio, M. Plantamura, M. Santosabato, T. Francavilla, S. Ottaviano, L. M. Specchio

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.

Translated title of the contributionEfficacy and safety of Levetiracetam as add-on therapy in patients with refractory partial epilepsy: A long-term, open-label, prospective study
Original languageItalian
Pages (from-to)195-197
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number125-126
Publication statusPublished - Jul 2004

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy and safety of Levetiracetam as add-on therapy in patients with refractory partial epilepsy: A long-term, open-label, prospective study'. Together they form a unique fingerprint.

Cite this